PURAPHARM released its interim results, with a loss attributable to shareholders of HKD 21.806 million, an increase of 16.7% year-on-year
PURAPHARM released its interim results for the period ending June 30, 2025, reporting revenue of HKD 172 million, a year-on-year decrease of 17.02%; a loss attributable to shareholders of HKD 21.806 million, a year-on-year increase of 16.7%; and a basic loss per share of HKD 0.0552. The revenue decline was mainly due to a slowdown in consumer spending in Hong Kong and intense market competition, while the group has reduced its focus on the hospital channel in the Chinese concentrated traditional Chinese medicine granule market
According to the Zhitong Finance APP, PURAPHARM (01498) released its interim results for the six months ending June 30, 2025, reporting revenue of HKD 172 million, a year-on-year decrease of 17.02%; the loss attributable to equity holders of the parent company was HKD 21.806 million, an increase of 16.7% year-on-year; basic loss per share was HKD 0.0552.
The announcement stated that the decrease in revenue was mainly due to the slowdown in consumer spending in Hong Kong and intense market competition, as well as the group's continued weakening of its focus on the hospital channel in the Chinese concentrated traditional Chinese medicine granule market
